<scp>DUAL</scp>I China: Improved glycemic control with<scp>IDegLira</scp>versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs

Wang, Weiqing; Agner, Bue F Ross; Luo, Bin; Liu, Lei; Liu, Ming; Peng, Yongde; Qu, Shen; Stachlewska, Karolina; Wang, Guixia; Yuan, Guoyue; Zhang, Qiu; Ning, Guang

doi:10.1111/1753-0407.13286

Cited by 9 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results presented here are fairly similar to those observed with the other approved fixed‐ratio combination preparation, IDegLira (insulin degludec [IDeg] + liraglutide [Lira]), versus IDeg or Lira in 720 Chinese participants in a recently conducted study 23,24 . After 26 weeks, mean HbA1c decreased from 66 mmol/mol (8.2%) to 48 mmol/mol (6.5%) for participants receiving IDegLira, with 77% of participants achieving HbA1c <53 mmol/mol (<7%) and 41% of participants reaching HbA1c <53 mmol/mol (<7%) without weight gain 24 .…”

Section: Discussionsupporting

confidence: 84%

Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan‐O‐AP randomized controlled trial

Yang

Dong

et al. 2022

Diabetes Obesity Metabolism

Self Cite

View full text Add to dashboard Cite

Aims: To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/ mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with suboptimally controlled type 2 diabetes (T2D) on metformin with or without a second oral antihyperglycaemic drug (OAD).Materials and Methods: LixiLan-O-AP (NCT03798054) was a 24-week multicentre study in adults (n = 878, mean age 56.0 years, mean body mass index 26.0 kg/m 2 ) with glycated haemoglobin (HbA1c) levels ≥53 mmol/mol (7%) and ≤97 mmol/mol (11%) on OAD(s), randomized (2:2:1) to open-label once-daily iGlarLixi, iGlar or Lixi while on continued metformin ± sodium-glucose cotransporter-2 inhibitors. The primary efficacy endpoint was change in HbA1c.Results: After 24 weeks, greater reductions in HbA1c from baseline (67 mmol/mol; 8.3%) were seen with iGlarLixi (À21 mmol/mol; À1.9%) compared with iGlar (À16 mmol/mol; À1.4%; P < 0.0001) and Lixi (À10 mmol/mol; À0.9%; P < 0.0001). Greater proportions of participants achieved HbA1c <53 mmol/mol (<7%) with iGlarLixi versus iGlar or Lixi (79%, 60% and 30%, respectively), overall and as composite endpoints including weight and hypoglycaemia. iGlarLixi improved 2-hour postprandial glucose versus iGlar and Lixi and mitigated the weight gain seen with iGlar (least squares mean difference À1.1 kg; P < 0.0001). Documented ≤3.9 mmol/L (≤70 mg/dL) hypoglycaemia was similar between iGlarLixi and iGlar (both 3.38 events per participantyear). The incidence rates of nausea and vomiting were lower with iGlarLixi (14% and 6%) than Lixi (21% and 11%).Conclusions: iGlarLixi achieved significant HbA1c reductions, to nearnormoglycaemic levels, compared with iGlar or Lixi, with no meaningful additional risk of hypoglycaemia and mitigated body weight gain versus iGlar, with fewer gastrointestinal adverse events versus Lixi. iGlarLixi with specifically adapted ratios may

show abstract

Section: Discussionsupporting

confidence: 84%

Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan‐O‐AP randomized controlled trial

Yang

Dong

et al. 2022

Diabetes Obesity Metabolism

Self Cite

View full text Add to dashboard Cite

show abstract

“…DUALI was used in base case, while DUAL II was used for scenario analysis. Long-term projections of costs and clinical outcomes based on data from the DUALI [ 17 ] and DUALII [ 16 ] China clinical trial study were made using the IQVIA CORE Diabetes Model Version 9.0 (IQVIA, Basel, Switzerland), a previously published and validated model of type 2 diabetes [ 18 – 20 ]. The non-product-specific diabetes policy analysis tool is capable of conducting real-time simulations that incorporate different treatment regimens.…”

Section: Methodsmentioning

confidence: 99%

Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients

Wei,

Wang,

Huang

et al. 2023

Diabetol Metab Syndr

View full text Add to dashboard Cite

Background and aims To assess the cost-effectiveness of utilizing IDegLira in comparison to other treatment regimens ( liraglutide and degludec) in managing type 2 diabetes, taking into account the Chinese healthcare system’s perspective. Methods The clinical data were obtained from the randomized controlled trials (RCTs) of the DUAL I and DUAL II evidence studies that took place in China. To estimate the lifetime quality-adjusted life-years (QALYs) and direct medical costs of patients receiving different treatment strategies from a long-term perspective, the IQVIA CORE Diabetes Model version 9.0 (IQVIA, Basel, Switzerland) was utilized. The costs were evaluated from the perspective of the China National Health System. Future costs and clinical benefits were discounted annually at 5%, and sensitivity analyses were conducted. Results IDegLira was projected to reduce the incidence of diabetes-related complications and improve quality-adjusted life expectancy (QALE) versus liraglutide and degludec. A survival benefit was observed with IDegLira over Liraglutide (0.073 years). Lifetime costs were lower by Chinese yuan (CNY) 27,945 on IDegLira than on Liraglutide therapy. A similar survival benefit was observed with IDegLira over degludec (0.068 years). Lifetime costs were lower by CNY 1196 on IDegLira than on degludec therapy. Therefore, IDegLira was found to be cost-effective versus liraglutide and degludec with incremental cost-effectiveness ratios of Dominant per QALY gained, respectively, under the threshold of three times the gross domestic product (GDP) per capita in China. Conclusion IDegLira is a cost-effective hypoglycemic treatment option that delivers positive clinical outcomes while also reducing costs for Chinese patients living with type 2 diabetes.

show abstract

“…The LixiLan series studies and the DUAL series studies have verified the efficacy and safety of Insulin Glargine–Lixisenatide FRC and Insulin Degludec–Liraglutide FRC, respectively, in patients with T2DM. These FRC regimens have been confirmed to improve glucose levels in patients whose glycemic control cannot be well regulated with oral glycemic drugs, basal insulin, or GLP‐1RAs 120–125 . Post hoc analysis of the LixiLan‐L/O study and multiple DUAL series studies have indicated that, compared with therapies with a single component, Insulin Glargine–Lixisenatide FRC and Insulin Degludec–Liraglutide FRC are effective, safe, and tolerable in older patients 116,117,126 …”

Section: Chapter 8: Glycemic Medications and Treatment Strategies For...mentioning

confidence: 99%

“…These FRC regimens have been confirmed to improve glucose levels in patients whose glycemic control cannot be well regulated with oral glycemic drugs, basal insulin, or GLP‐1RAs. 120 , 121 , 122 , 123 , 124 , 125 Post hoc analysis of the LixiLan‐L/O study and multiple DUAL series studies have indicated that, compared with therapies with a single component, Insulin Glargine–Lixisenatide FRC and Insulin Degludec–Liraglutide FRC are effective, safe, and tolerable in older patients. 116 , 117 , 126 …”

Section: Chapter 8: Glycemic Medications and Treatment Strategies For...mentioning

confidence: 99%

Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)

Guo,

Xiao

2024

Aging Medicine

View full text Add to dashboard Cite

With the deepening of aging in China, the prevalence of diabetes in older people has increased noticeably, and standardized diabetes management is critical for improving clinical outcomes of diabetes in older people. In 2021, the National Center of Gerontology, Chinese Society of Geriatrics, and Diabetes Professional Committee of Chinese Aging Well Association organized experts to write the first guideline for diabetes diagnosis and treatment in older people in China, the Guideline for the Management of Diabetes Mellitus in the Elderly in China (2021 Edition). The guideline emphasizes that older patients with diabetes are a highly heterogeneous group requiring comprehensive assessment and stratified and individualized management strategies. The guideline proposes simple treatments and de‐intensified treatment strategies for older patients with diabetes. This edition of the guideline provides clinicians with practical and operable clinical guidance, thus greatly contributing to the comprehensive and full‐cycle standardized management of older patients with diabetes in China and promoting the extensive development of clinical and basic research on diabetes in older people and related fields. In the past 3 years, evidence‐based medicine for older patients with diabetes and related fields has further advanced, and new treatment concepts, drugs, and technologies have been developed. The guideline editorial committee promptly updated the first edition of the guideline and compiled the Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition). More precise management paths for older patients with diabetes are proposed, for achieving continued standardization of the management of older Chinese patients with diabetes and improving their clinical outcomes.

show abstract

DUALI China: Improved glycemic control withIDegLiraversus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs

Cited by 9 publications

References 27 publications

Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan‐O‐AP randomized controlled trial

Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan‐O‐AP randomized controlled trial

Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients

Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)

Contact Info

Product

Resources

About